Literature DB >> 8687493

Differential distribution of free and bound glutathione and cyst(e)ine in human blood.

B J Mills1, C A Lang.   

Abstract

The redox status of free and bound glutathione (GSH) and cyst(e)ine (Cys) is altered by oxidative stress, drugs, and disease. Most studies measure only their free forms and not the bound forms, which may have a crucial protective role. For this reason, we determined free and bound, reduced and oxidized GSH and Cys in whole blood, red cells, and plasma of human blood from healthy adults. Distinct compartments of GSH and Cys were found. In whole blood, > 99% GSH was in red cells, of which 16% was bound. GSH values were the same for red cells in whole blood or in cells isolated from the same samples. Only 0.5% of GSH was in plasma, all of which was bound. In contrast, 97% of Cys was in plasma and only 3% in red cells. This was a remarkable separation of these closely related metabolites in the same tissue. In plasma, 60% of Cys was bound. Also, strong correlations were shown of bound vs free Cys and also vs free plus bound Cys. The bound Cys was more constant and suggested that it is a metabolic reserve. Our findings demonstrate the occurrence of significant bound forms of GSH and Cys and have implications for future studies in disease and toxicology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8687493     DOI: 10.1016/0006-2952(96)00241-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

Review 1.  Efficacy of screening immune system function in at-risk newborns.

Authors:  Christopher J Pavlovski
Journal:  Australas Med J       Date:  2014-07-31

2.  Metabolomics of ADSOL (AS-1) red blood cell storage.

Authors:  John D Roback; Cassandra D Josephson; Edmund K Waller; James L Newman; Sulaiman Karatela; Karan Uppal; Dean P Jones; James C Zimring; Larry J Dumont
Journal:  Transfus Med Rev       Date:  2014-02-05

3.  Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity.

Authors:  D J Naisbitt; S J Hough; H J Gill; M Pirmohamed; N R Kitteringham; B K Park
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

4.  N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions.

Authors:  Leonardo F Ferreira; Kenneth S Campbell; Michael B Reid
Journal:  Int J Sport Nutr Exerc Metab       Date:  2011-04       Impact factor: 4.599

Review 5.  Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment.

Authors:  D J Naisbitt; S F Gordon; M Pirmohamed; B K Park
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

6.  Detection of multiple globin monoadducts and cross-links after in vitro exposure of rat erythrocytes to S-(1,2-dichlorovinyl)-L-cysteine sulfoxide and after in vivo treatment of rats with S-(1,2-dichlorovinyl)-L-cysteine sulfoxide.

Authors:  Nella Barshteyn; Adnan A Elfarra
Journal:  Chem Res Toxicol       Date:  2008-08-06       Impact factor: 3.739

Review 7.  Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.

Authors:  Mallory R Gordon; Mine Canakci; Longyu Li; Jiaming Zhuang; Barbara Osborne; S Thayumanavan
Journal:  Bioconjug Chem       Date:  2015-09-10       Impact factor: 4.774

Review 8.  State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.

Authors:  Charlene M Dawidczyk; Chloe Kim; Jea Ho Park; Luisa M Russell; Kwan Hyi Lee; Martin G Pomper; Peter C Searson
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

9.  Effects of randomized supplementation of methionine or alanine on cysteine and glutathione production during the early phase of treatment of children with edematous malnutrition.

Authors:  Curtis O Green; Asha V Badaloo; Jean W Hsu; Carolyn Taylor-Bryan; Marvin Reid; Terrence Forrester; Farook Jahoor
Journal:  Am J Clin Nutr       Date:  2014-03-05       Impact factor: 7.045

10.  In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.

Authors:  Leonid Gaidukov; Dganit Bar; Shiri Yacobson; Esmira Naftali; Olga Kaufman; Rinat Tabakman; Dan S Tawfik; Etgar Levy-Nissenbaum
Journal:  BMC Clin Pharmacol       Date:  2009-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.